Planning of external beam radiotherapy for prostate cancer guided by PET/CT - Abstract

In this paper, we give an overview of articles on non-choline tracers for PET/CT for patients with prostate cancer and planning of radiotherapy guided by PET/CT.

Nineteen articles described 11C-Acetate PET/CT. Of 629 patients 483 (77%, 95% CI 74% - 80%) had positive 11C-Acetate PET/CT scans. Five articles described 18F-FACBC PET/CT. Of 174 patients 127 (73%, 95% CI 68% - 78%) had positive scans. Both tracers detected local lesions, lesions in regional lymph nodes, and distant organs. Ten articles described 18F-NaF PET/CT and found that 1289 of 3918 patients (33%) had positive reactive lesions in bones. PET/CT scan can guide external beam radiotherapy (EBRT) planning for patients with loco-regional prostate cancer. In six studies with 178 patients with localized prostate cancer, PET/CT pointed out dominant intraprostatic lesions (DIL). Oncologists gave the patients EBRT to the whole prostate and a simultaneously integrated boost to the DIL. Four studies with 254 patients described planning of EBRT for patients with PET-positive lymph nodes. During follow-up, 15 of 29 node-positive patients remained in remission for median 28 months (range 14 to 50 months). Most articles described 11C- and 18F-Choline as PET/CT tracers. In addition, 11C-Acetate and 18F-FACBC may be useful tracers. Planning of radiotherapy for localized prostate cancer guided by MRI or PET/CT is an investigational method. Current clinical controlled trials of the method evaluate whether it may improve overall survival.

Written by:
Von Eyben FE, Kairemo K, Kiljunen T, Joensuu T.   Are you the author?
Center of Tobacco Control Research, Birkevej 17, DK-5230 Odense M, Denmark.  

Reference: Curr Radiopharm. 2015 Mar 16. Epub ahead of print.

PubMed Abstract
PMID: 25808958

Beyond the Abstract Prostate Cancer Section